AngioDynamics, Inc. (ANGO)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$15.20-1.75%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · ANGO
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | May 2026 | May 2025 | May 2024 | May 2023 | May 2022 | May 2021 | May 2020 | May 2019 | May 2018 | May 2017 | May 2016 | May 2015 | May 2014 | May 2013 | May 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 320.2 | 320.2 | 292.5 | 303.9 | 338.8 | 316.2 | 291.0 | 264.2 | 270.6 | 261.7 | 349.6 | 353.9 | 356.5 | 354.4 | 341.9 | 221.9 |
| Total Revenues | — | — | — | — | — | — | 291.0 | 264.2 | 270.6 | 261.7 | 349.6 | 353.9 | 356.5 | 354.4 | 341.9 | 221.9 |
| Cost of Revenues | 145.3 | 145.3 | 134.8 | 149.2 | 164.5 | 150.5 | 134.2 | 113.9 | 114.6 | 117.8 | — | — | — | — | — | — |
| Gross Profit | 174.9 | 174.9 | 157.7 | 154.7 | 174.2 | 165.7 | 156.8 | 150.3 | 156.0 | 143.9 | 144.0 | 174.3 | 175.8 | 180.2 | 168.5 | 125.3 |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 29.4 | 29.4 | 26.2 | 31.5 | 29.9 | 30.7 | 36.4 | 29.7 | 28.3 | 24.3 | 24.1 | 25.1 | 26.6 | 28.1 | 26.1 | 20.5 |
| Operating Income | (39.9) | (39.9) | (40.0) | (192.4) | (51.2) | (28.5) | (35.3) | (167.1) | (9.4) | (14.2) | (11.2) | 1.0 | (3.4) | 10.5 | 5.2 | (5.2) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | (1.6) | 2.7 | 0.7 | 0.9 | 0.9 | 5.1 | 3.1 | 2.8 | 3.4 | 3.2 | 3.7 | 5.3 | 0.5 |
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.1 | 1.1 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | — | 3.4 | 3.2 | 3.7 | 5.2 | (0.6) |
| EBT, Incl. Unusual Items | (36.3) | (36.3) | (34.0) | (191.6) | (54.4) | (29.9) | (36.1) | (168.1) | (14.7) | (17.3) | (14.3) | (3.3) | (8.1) | 5.2 | (1.3) | (5.7) |
| Income Tax Expense | 0.4 | 0.4 | (0.0) | (7.3) | (2.0) | (3.4) | (4.5) | (1.3) | (3.6) | (11.0) | (7.2) | 40.3 | (4.7) | (9.2) | (0.3) | (0.3) |
| Net Income | ||||||||||||||||
| Net Income | (36.7) | (36.7) | (34.0) | (184.3) | (52.4) | (26.5) | (31.5) | (166.8) | 61.3 | 16.3 | 5.0 | (43.6) | (3.4) | 2.3 | (1.1) | (5.3) |
| Per Share | ||||||||||||||||
| Basic EPS | — | (0.88) | (0.83) | (4.59) | (1.33) | (0.68) | (0.82) | (4.39) | 1.64 | 0.44 | 0.14 | (1.21) | (0.09) | 0.07 | (0.03) | (0.20) |
| Diluted EPS | — | (0.88) | (0.83) | (4.59) | (1.33) | (0.68) | (0.82) | (4.39) | 1.64 | 0.44 | 0.14 | (1.21) | (0.09) | 0.07 | (0.03) | (0.20) |
| Basic Weighted Avg Shares | — | 41.5 | 40.9 | 40.2 | 39.5 | 39.0 | 38.3 | 38.0 | 37.5 | 37.1 | 36.6 | 36.2 | 35.7 | 35.1 | 34.8 | 25.4 |
| Diluted Weighted Avg Shares | — | 41.5 | 40.9 | 40.2 | 39.5 | 39.0 | 38.3 | 38.0 | 37.5 | 37.1 | 36.6 | 36.2 | 35.7 | 35.4 | 34.8 | 25.4 |
| Supplemental | ||||||||||||||||
| EBITDA | — | (17.0) | (14.2) | (164.7) | (20.3) | 0.9 | (9.4) | (143.3) | 16.5 | 9.0 | 13.6 | 29.1 | 26.4 | 38.8 | 32.5 | 9.4 |
| EBIT | (39.9) | (39.9) | (40.0) | (192.4) | (51.2) | (28.5) | (35.3) | (167.1) | (9.4) | (14.2) | (11.2) | 1.0 | (3.4) | 10.5 | 5.2 | (5.2) |
| Effective Tax Rate | -1.2% | — | — | — | 3.7% | 11.4% | 12.5% | 0.8% | 24.2% | 63.9% | 50.7% | -1240.0% | 58.3% | -177.4% | 21.4% | 5.7% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.